Hong Kong SAR

Maanshan Iron & Steel is seeking shareholder approval to raise up to $500m from a debut convertible bond — the first time in 25 years it is tapping equity investors for funds.

Chinese firm Weimob is seeking the greenlight to float in Hong Kong, having filed a draft prospectus with the city’s bourse on Monday.

Hong Kong has had its first taste of a pre-revenue biotechnology stock with the listing by Ascletis Pharma. Unfortunately, the company got caught up in a wave of volatility and the shares have not fared well. It was not a good start for biotech but the sector should not be judged by this one deal, as it was just the first from a bulging IPO pipeline.

Haidilao International Holding plans to launch its $1bn IPO in Hong Kong by the end of the month, according to bankers working on the deal.

Shanghai Junshi Biosciences is eyeing a $500m IPO in Hong Kong, having filed a draft prospectus with the city’s stock exchange.

China Industrial Securities International Financial Group, a subsidiary of Industrial Securities, has launched a debut loan of up to HK$4bn ($510m).

China Everbright Water has mooted a dual-listing of its shares on the Main Board of the Hong Kong Stock Exchange, in a deal bankers say could raise $200m.

Pascal Fischer has started his new post of head of global markets in Asia-Pacific at BNP Paribas, based in Hong Kong.

Trading volume for RMB futures contracts are up in Hong Kong and Dubai, activity on Bond Connect slows down in July after a strong uptick in the previous month, and the FX watchdog shuts the door on new inbound and outbound investment quotas.

Four former Credit Suisse loans bankers who left the bank earlier this year have resurfaced in the market, according to sources.

Minsheng Financial Leasing, a subsidiary of China Minsheng Bank, has returned to the loan market for a $300m three year borrowing.

Natixis has made three senior appointments in Hong Kong to support its growing investment banking activities in Asia Pacific.